Ammar A. Javed, MD
@ammaraj.bsky.social
Assistant Professor @NYULangone focusing on research on Pancreatic Neoplasms | Founder PANC-PALS Consortium | Past Postdoctoral Research Fellow @JohnsHopkins | @akuglobal
Reposted by Ammar A. Javed, MD
#HoraEst @ammaraj.bsky.social 🇺🇸 #PhD ceremony today in A’dam 🇳🇱
⏩️Amazing work!! #Thesis hdl.handle.net/11245.1/d2bd0a…#PhDhD team: Chris Wolfgang, Jin He, Lois Daamen
@amsterdamumc.bsky.social @pancpals.bsky.social @dpcgofficial.bsky.socia#PancreaticCancerer
⏩️Amazing work!! #Thesis hdl.handle.net/11245.1/d2bd0a…#PhDhD team: Chris Wolfgang, Jin He, Lois Daamen
@amsterdamumc.bsky.social @pancpals.bsky.social @dpcgofficial.bsky.socia#PancreaticCancerer
May 15, 2025 at 4:13 PM
#HoraEst @ammaraj.bsky.social 🇺🇸 #PhD ceremony today in A’dam 🇳🇱
⏩️Amazing work!! #Thesis hdl.handle.net/11245.1/d2bd0a…#PhDhD team: Chris Wolfgang, Jin He, Lois Daamen
@amsterdamumc.bsky.social @pancpals.bsky.social @dpcgofficial.bsky.socia#PancreaticCancerer
⏩️Amazing work!! #Thesis hdl.handle.net/11245.1/d2bd0a…#PhDhD team: Chris Wolfgang, Jin He, Lois Daamen
@amsterdamumc.bsky.social @pancpals.bsky.social @dpcgofficial.bsky.socia#PancreaticCancerer
Reposted by Ammar A. Javed, MD
May 5, 2025 at 4:06 PM
Reposted by Ammar A. Javed, MD
Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
April 24, 2025 at 3:01 PM
Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030.
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs
Reposted by Ammar A. Javed, MD
We are honored to see the #PANCPALS consortium expanding the last few weeks! Already over 80 committed sites globally, and still growing 💪👀
Join us now! Find the joining questionnaire on pancpals.com/joining-ques...
@ammaraj.bsky.social @marcbesselink.bsky.social
Join us now! Find the joining questionnaire on pancpals.com/joining-ques...
@ammaraj.bsky.social @marcbesselink.bsky.social
April 4, 2025 at 8:37 PM
We are honored to see the #PANCPALS consortium expanding the last few weeks! Already over 80 committed sites globally, and still growing 💪👀
Join us now! Find the joining questionnaire on pancpals.com/joining-ques...
@ammaraj.bsky.social @marcbesselink.bsky.social
Join us now! Find the joining questionnaire on pancpals.com/joining-ques...
@ammaraj.bsky.social @marcbesselink.bsky.social
Reposted by Ammar A. Javed, MD
March 22, 2025 at 4:02 PM
Reposted by Ammar A. Javed, MD
March 21, 2025 at 2:53 PM
Reposted by Ammar A. Javed, MD
Preperations underway for the #AHPBA Miami 2025 at the PANC-PALS HQ! 🙌🏻📂
Come visit us at our booth! #AHPBA #PANCPALS
@ammaraj.bsky.social
Come visit us at our booth! #AHPBA #PANCPALS
@ammaraj.bsky.social
March 14, 2025 at 4:43 PM
Preperations underway for the #AHPBA Miami 2025 at the PANC-PALS HQ! 🙌🏻📂
Come visit us at our booth! #AHPBA #PANCPALS
@ammaraj.bsky.social
Come visit us at our booth! #AHPBA #PANCPALS
@ammaraj.bsky.social
Reposted by Ammar A. Javed, MD
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine had no signs of relapse after three years.
Dr. Vinod Balachandran from @mskcancercenter.bsky.social joins us to discuss the results and what they could mean for cancer treatment.
Dr. Vinod Balachandran from @mskcancercenter.bsky.social joins us to discuss the results and what they could mean for cancer treatment.
A Vaccine For Pancreatic Cancer Continues To Show Promise
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.
buff.ly
February 21, 2025 at 7:41 PM
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine had no signs of relapse after three years.
Dr. Vinod Balachandran from @mskcancercenter.bsky.social joins us to discuss the results and what they could mean for cancer treatment.
Dr. Vinod Balachandran from @mskcancercenter.bsky.social joins us to discuss the results and what they could mean for cancer treatment.
Reposted by Ammar A. Javed, MD
February 13, 2025 at 8:57 PM
Reposted by Ammar A. Javed, MD
What are the prognostic factors in patients with resected #PDAC that receive NAT? 💊🏥
#PANCPALS published last week in Annals of Surgery!
Key: prognostic factors for OS differ between chemo-naive and NAT patients.
Find the prognostic tool on our website soon! 💪
@ammaraj.bsky.social
#PANCPALS published last week in Annals of Surgery!
Key: prognostic factors for OS differ between chemo-naive and NAT patients.
Find the prognostic tool on our website soon! 💪
@ammaraj.bsky.social
February 10, 2025 at 4:42 PM
What are the prognostic factors in patients with resected #PDAC that receive NAT? 💊🏥
#PANCPALS published last week in Annals of Surgery!
Key: prognostic factors for OS differ between chemo-naive and NAT patients.
Find the prognostic tool on our website soon! 💪
@ammaraj.bsky.social
#PANCPALS published last week in Annals of Surgery!
Key: prognostic factors for OS differ between chemo-naive and NAT patients.
Find the prognostic tool on our website soon! 💪
@ammaraj.bsky.social
Reposted by Ammar A. Javed, MD
🧪 Researchers are leaving X for Bluesky, favoring its chronological feed and low-sensationalism. Philipp Lorenz-Spreen calls it “a good boring.” The algorithm-free platform reduces negative social media effects and boosts smaller accounts but its smaller user base limits outreach. #AcademicSky
As academic Bluesky grows, researchers find strengths—and shortcomings
Platform fosters collegial interactions among scientists, but potentially limits interactions beyond the academic community
www.science.org
January 8, 2025 at 3:26 PM
🧪 Researchers are leaving X for Bluesky, favoring its chronological feed and low-sensationalism. Philipp Lorenz-Spreen calls it “a good boring.” The algorithm-free platform reduces negative social media effects and boosts smaller accounts but its smaller user base limits outreach. #AcademicSky
Reposted by Ammar A. Javed, MD
#Pancreaticcancer patients who participate in clinical research have better outcomes. 🔬🧪 We're dedicated to helping patients understand their options and find trials that are right for them.
Visit our clinical trials hub at pancan.org/clinicaltrials or contact us today for personalized support. 💜
Visit our clinical trials hub at pancan.org/clinicaltrials or contact us today for personalized support. 💜
January 8, 2025 at 8:16 PM
#Pancreaticcancer patients who participate in clinical research have better outcomes. 🔬🧪 We're dedicated to helping patients understand their options and find trials that are right for them.
Visit our clinical trials hub at pancan.org/clinicaltrials or contact us today for personalized support. 💜
Visit our clinical trials hub at pancan.org/clinicaltrials or contact us today for personalized support. 💜
Reposted by Ammar A. Javed, MD
Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis
academic.oup.com/bjs/article-...
academic.oup.com/bjs/article-...
Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis
In this meta-analysis, the most common actionable and undruggable mutations in resected intrahepatic cholangiocarcinoma are determined. Among the heterogen
academic.oup.com
January 2, 2025 at 11:54 PM
Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis
academic.oup.com/bjs/article-...
academic.oup.com/bjs/article-...
Just another night in the big 🍎
November 24, 2024 at 12:02 AM
Just another night in the big 🍎
Reposted by Ammar A. Javed, MD
President-elect Trump has picked Dr. Marty Makary, to lead the Federal Drug Administration.
thehill.com/policy/healt...
thehill.com/policy/healt...
thehill.com
November 23, 2024 at 4:09 AM
President-elect Trump has picked Dr. Marty Makary, to lead the Federal Drug Administration.
thehill.com/policy/healt...
thehill.com/policy/healt...